Spark Therapeutics (NASDAQ:ONCE) Downgraded to “Sell” at ValuEngine

ValuEngine downgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a hold rating to a sell rating in a research note issued to investors on Tuesday, November 14th.

ONCE has been the subject of several other research reports. Jefferies Group reiterated a buy rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. SunTrust Banks set a $101.00 price objective on Spark Therapeutics and gave the company a buy rating in a research report on Monday, October 16th. Cowen reiterated a buy rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Royal Bank Of Canada cut their price objective on Spark Therapeutics from $100.00 to $98.00 and set an outperform rating for the company in a research report on Wednesday, November 8th. Finally, Cantor Fitzgerald set a $94.00 price objective on Spark Therapeutics and gave the company a buy rating in a research report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $90.36.

Spark Therapeutics (NASDAQ ONCE) traded down $3.15 during trading on Tuesday, hitting $70.08. The company had a trading volume of 666,519 shares, compared to its average volume of 402,526. Spark Therapeutics has a 1-year low of $47.03 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. During the same quarter last year, the business earned ($1.07) EPS. Spark Therapeutics’s quarterly revenue was up 45.8% compared to the same quarter last year. analysts forecast that Spark Therapeutics will post -7.6 earnings per share for the current fiscal year.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares of the company’s stock, valued at $876,750. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the completion of the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at $18,524,400. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,083,309 shares of company stock valued at $91,004,945. Insiders own 7.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. boosted its position in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the second quarter worth about $143,000. BNP Paribas Arbitrage SA boosted its position in shares of Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. boosted its position in shares of Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in shares of Spark Therapeutics during the third quarter worth about $225,000. 94.93% of the stock is owned by institutional investors.

WARNING: This report was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://baseballnewssource.com/markets/spark-therapeutics-inc-once-cut-to-sell-at-valuengine/1782560.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.